NEW YORK (TheStreet) -- Welcome to Don Dion's "Daily ETF Winners and Losers." Be sure to stop by each day to find out which ETFs are gaining or losing.
iPath S&P 500 VIX Short Term Futures ETN (VXX) 9.1%
The markets are struggling to follow through on Wednesday's gains, but they are weighed down by weak jobless claims data and broad market jitters.This scenario bodes well for ETNs that follow the fear-tracking VIX. VXX is witnessing its third day of upward action and is currently trading at June highs. iPath S&P 500 VIX Mid Term Futures ETN (VXZ) is gaining ground as well. The fund's jump is helping it test its 50-day moving average once again. iShares Barclays 20+ Year Treasury Bond Fund (TLT) 2.0% Long-term U.S. treasuries have seen a steep climb over the past week as the market's shaky action drives investors into defensive assets. With these gains, the fund is nearing 2010 highs. Not surprisingly, the inverse-tracking ProShares UltraShort 20+ Year Treasury Bond ETF (TBT) is tumbling, suffering its eighth consecutive day of losses. PowerShares DB U.S. Dollar Index Bullish Portfolio (UUP) 1.4% In the same fashion as the TLT, the U.S. dollar is benefiting as investors steer clear of risky asset classes in an effort to seek shelter from the market's downward action. UUP's gains have pushed the fund back to its 50-day moving average. Despite investor desire for protection, gold is seeing relatively unchanged action. Meanwhile, silver, palladium and platinum are seeing pronounced losses.
LosersGlobal X Norway ETF (NORW) -8.1% The economic issues facing Europe have once again fallen into focus leading a number of ETFs lower. Some of the funds leading the retreat include NORW, iShares MSCI Turkey Investable Market Index Fund (TUR) and iShares MSCI Sweden Index Fund (EWD). This region of the globe must be approached with extreme caution. First Trust NYSE Arca Biotech Index Fund (FBT) -7.6% News of weak sales for its prostate cancer drug, Provenge, sent shares of closely watched biotechnology player Dendreon (DNDN) spiraling, dropping over 65%. This tumble is weighing heavily across the biotech sector, leading ETFs like FBT and iShares Nasdaq Biotechnology Index Fund (IBB) to suffer heavy losses.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV